DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AMANTA HEALTHCARE LIMITED (AMANTA) share price today?

AMANTA HEALTHCARE LIMITED (AMANTA) is trading at ₹168 on the NSE, up 1.65% on the day. Source: DocStoX.

What is the PE ratio of AMANTA HEALTHCARE LIMITED?

AMANTA HEALTHCARE LIMITED has a price-to-earnings (PE) ratio of 46.1 in the Healthcare sector.

What is the market capitalisation of AMANTA HEALTHCARE LIMITED?

AMANTA HEALTHCARE LIMITED has a market capitalisation of approximately ₹658 crore.

AMANTA HEALTHCARE LIMITED

AMANTA·NSE·Healthcare

₹168.00▲ +2.73 (+1.65%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹161.97

₹168.57

52W₹92

₹18978%

Open

₹161.97

High

₹168.57

Low

₹161.97

Prev Close

₹165.27

Volume

1.25L

VWAP

₹166.30

Snapshot

Key fundamentals

Market Cap

₹658 Cr

P/E Ratio

46.15Expensive

P/B Ratio

3.24

EPS

₹3.64

Book Value

₹56.71

ROE

10.89%Average

ROCE

15.00%Decent

Dividend Yield

0.00%

Debt / Equity

1.11Elevated

Face Value

₹10.00

52W High

₹189.00

52W Low

₹92.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹57

▼ 66.0%downside

Trading at ₹168 — 66% above our estimate

BearFair valueBull

₹48₹57₹68

/100

Business quality — Watch the fundamentals

Growth 1Profitability 19Efficiency 26Valuation 27

Plain English

Our view

A steady, established business
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

11% ROE fading to 14% over ~3 yrs, on ₹57 book

₹54

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹68

Analyst target

No analyst coverage

—

Blended fair value₹57

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

46.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

10.9%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

1.11Elevated

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹658 Cr

P/B

3.24

EPS

₹3.64

Div Yield

—

What changed

Recent changes

Foreign investors-0.3% stake last quarter
Domestic institutions+1.6% stake last quarter
Promoters+0.16% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 46.1×

Growth

Slow

+4% rev CAGR

Profitability

Modest

10.9% ROE

Financial health

Leveraged

D/E 1.11

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹207.99L Cr

Trades395

VWAP₹166.30

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+3.6%

+11.0%

10Y

—

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has delivered good profit growth of 22.4% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 3.16 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 10.9% over past five years.
Company has a low return on equity of 10.1% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 0.16 pts; foreign investors sold 0.25 pts; domestic institutions added 1.64 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

64%

Promoter

Promoters

63.7%+0.16

Public

22.6%-1.54

FII / FPI

0.8%-0.25

DII

12.9%+1.64

Total shareholders

15,222-959 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter63.72%

FII0.85%

DII12.88%

Public22.55%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions